Cancer in patients on Dapagliflozin and other antidiabetic treatment

Trial Identifier:	D1690R00007
Sponsor:	AstraZeneca
Start Date:	January 2017
Primary Completion Date:	January 2025
Study Completion Date:	January 2025
Condition:	Cancer - Other; Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Netherlands	Utrecht, Netherlands
United Kingdom	London, United Kingdom
USA, DE	Wilmington, DE, USA
USA, Washington DC	Washington DC, USA

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.